卡博替尼用于多西他赛后进展性转移性去势抵抗性前列腺癌:两项3期试验的联合分析
本文对COMET-1和COMET-2两项3期试验的1147例多西他赛后转移性去势抵抗性前列腺癌患者进行回顾性联合分析,评估卡博替尼对比对照组的生存获益。校正预后因素后,卡博替尼与更好的总生存相关(HR 0.80,95%CI 0.67-0.95;p=0.012),但任何预后亚组与治疗之间均无交互效应。作者认为可考虑在样本量更大的试验或基于分子生物标志物筛选的人群中进一步研究卡博替尼。
要点
- 两项3期试验共纳入1147例多西他赛后mCRPC患者(COMET-1 1028例,COMET-2 119例)。
- 年龄、无病间期、血红蛋白、PSA、碱性磷酸酶、白蛋白、骨扫描病灶面积、LDH、ECOG体能状态和疼痛均为OS的预后因素(均p<0.05)。
- 校正预后因素后卡博替尼与更好的OS相关(HR 0.80,95%CI 0.67-0.95;p=0.012),但各预后组与治疗间无交互效应。
核心结论
- 校正预后因素后,卡博替尼与更好的总生存相关(HR 0.80,95%CI 0.67-0.95;p=0.012)。
- 卡博替尼与对照组的生存效应在任何预后因素亚组间均无交互作用。
- 作者认为可考虑在样本量更大的试验或基于分子生物标志物的合理患者人群中进一步研究卡博替尼。
研究设计与样本
- 对COMET-1和COMET-2两项3期试验的联合数据集进行回顾性分析。
- 共纳入1147例多西他赛后转移性去势抵抗性前列腺癌患者(COMET-1 1028例,COMET-2 119例)。
- 采用Cox比例风险回归模型评估预后因素预测生存的能力,并通过因素与卡博替尼的交互项评估潜在获益亚组。
- 所有检验均为双侧,p≤0.05认为有统计学意义。
主要发现
- 以下因素对OS具有预后价值:年龄、无病间期、血红蛋白、前列腺特异性抗原、碱性磷酸酶、白蛋白、骨扫描病灶面积、乳酸脱氢酶、美国东部肿瘤协作组体能状态和疼痛(均p<0.05)。
- 卡博替尼与对照组之间在任何预后组中均无生存交互效应。
- 校正预后因素后,卡博替尼与更好的OS相关(HR 0.80,95%CI 0.67-0.95;p=0.012)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文为对两项3期试验的回顾性分析。
- 作者认为可能需要在样本量更大的试验或基于分子生物标志物的合理患者人群中进一步研究卡博替尼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two phase 3 trials, COMET-1 and COMET-2, have reported that cabozantinib did not significantly extend overall survival (OS) compared to prednisone and prednisone plus mitoxantrone, respectively, in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted a retrospective analysis of a combined data set from these trials to identify a benefit in subsets of patients according to prognostic risk factors. The prognostic ability of factors to predict survival was evaluated using Cox proportional hazards regression models. Evaluation of potential beneficial subsets was performed using interaction terms between factors and cabozantinib. All tests were two-sided and p≤0.05 was considered statistically significant. A total of 1147 post-docetaxel patients with mCRPC were available (1028 from COMET-1 and 119 from COMET-2). The following factors were prognostic for OS: age, disease-free interval, hemoglobin, prostate-specific antigen, alkaline phosphatase, albumin, bone scan lesion area, lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, and pain (all p<0.05). There was no interaction effect on survival between cabozantinib versus comparator arms and any prognostic group. After adjusting for prognostic factors, cabozantinib was associated with better OS (hazard ratio 0.80, 95% confidence interval 0.67-0.95; p=0.012). Further investigation of cabozantinib in a better-powered trial or a rational patient population based on a molecular biomarker may be warranted. PATIENT SUMMARY: Two phase 3 trials have reported no survival benefit for cabozantinib, a multitarget oral drug, in metastatic castration-resistant prostate cancer. This analysis pooled 1147 patients from these trials to identify a survival benefit for cabozantinib. This study suggests that further rational development may be justified.
引用
- Sonpavde GP, Pond GR, Fizazi K, et al. Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. Eur Urol Oncol. 2018. PMID: 31412002. doi:10.1016/j.euo.2018.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。